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Abstract
We conducted a nationwide, registry-based study to investigate the importance of 34 potential risk factors for coronavirus 
disease 2019 (COVID-19) diagnosis, hospitalization (with or without intensive care unit [ICU] admission), and subsequent 
all-cause mortality. The study population comprised all COVID-19 cases confirmed in Sweden by mid-September 2020 
(68,575 non-hospitalized, 2494 ICU hospitalized, and 13,589 non-ICU hospitalized) and 434,081 randomly sampled general-
population controls. Older age was the strongest risk factor for hospitalization, although the odds of ICU hospitalization 
decreased after 60–69 years and, after controlling for other risk factors, the odds of non-ICU hospitalization showed no 
trend after 40–49 years. Residence in a long-term care facility was associated with non-ICU hospitalization. Male sex and 
the presence of at least one investigated comorbidity or prescription medication were associated with both ICU and non-
ICU hospitalization. Three comorbidities associated with both ICU and non-ICU hospitalization were asthma, hypertension, 
and Down syndrome. History of cancer was not associated with COVID-19 hospitalization, but cancer in the past year was 
associated with non-ICU hospitalization, after controlling for other risk factors. Cardiovascular disease was weakly associ-
ated with non-ICU hospitalization for COVID-19, but not with ICU hospitalization, after adjustment for other risk factors. 
Excess mortality was observed in both hospitalized and non-hospitalized COVID-19 cases. These results confirm that severe 
COVID-19 is related to age, sex, and comorbidity in general. The study provides new evidence that hypertension, asthma, 
Down syndrome, and residence in a long-term care facility are associated with severe COVID-19.
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Introduction
In December 2019, the Chinese city of Wuhan experienced 
an outbreak of a severe form of pneumonia of unknown 
cause. By January 7, the pathogen had been identified as 
a novel coronavirus, the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) [1]. The disease was later des-
ignated coronavirus disease 2019 (COVID-19) by the World 
Health Organization [2]. Although a travel ban in and out of 
Wuhan was imposed [3], the virus spread around the globe, 
and COVID-19 was declared a global pandemic on March 
11, 2020 [2]. Consequently, there is a large public-health 
need to study risk factors for developing severe COVID-19. 
Such studies can help inform strategies for vaccination and 
disease prevention.
Observational studies have shown that older age, male 
sex, and comorbidity in general are important risk factors 
for developing severe COVID-19 [4–8]. However, the results 
of these studies are inconsistent for particular comorbidi-
ties, such as hypertension [5–9], respiratory diseases [4, 6, 
7], and cardiovascular disease [5, 7, 8]. Severe COVID-19 
has also been associated with demographic factors such as 
minority ethnicity and low income [7]. The limitations of 
previous observational studies include small sample size 
[5, 6, 10], focus on particular risk factors [11, 12], lack of 
general-population control group [4–6, 8–10], and focus on 
a few particular outcomes, such as COVID-19-related death 
[7, 12], in-hospital mortality [4, 5, 9], or intensive care unit 
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(ICU)/critical care admission [4, 5]. Therefore, we used data 
from Swedish national registries to investigate the impor-
tance of potential medical and demographic risk factors for 
COVID-19 diagnosis, hospitalization (with or without ICU 
admission), and subsequent all-cause mortality during the 
first wave of COVID-19.
Methods
Data
The Public Health Agency of Sweden provided data from 
its SmiNet database on all cases of COVID-19 confirmed 
in Sweden until mid-September 2020. Reporting confirmed 
cases to SmiNet is required by law. We did not have informa-
tion on the methods of testing used to diagnose the COVID-
19 cases. Only the first date of diagnosis or positive test for 
each individual was provided.
We obtained a control population by requesting that Sta-
tistics Sweden (the agency of government statistics) ran-
domly sample 5 non-diagnosed individuals for each COVID-
19 case. Each control was residing in Sweden on January 1, 
2020, and was alive on January 31, 2020. No matching was 
performed. Statistics Sweden also provided registry data on 
sex, year and month of birth, country of birth, highest level 
of completed education in 2018, disposable family income 
in 2018, home municipality (on December 31, 2019), and a 
pseudo-anonymized household identifier, indicating which 
persons lived at the same street address (on December 31, 
2019).
The Swedish National Board of Health and Welfare 
provided registry data on deaths, diagnoses, hospitaliza-
tions, prescription medication use, residence in long-term 
care facility, and use of homemaker service. All deaths in 
Sweden are recorded in the Cause of Death Register [13]. 
Diagnoses and hospitalizations are registered in the National 
Patient Register, to which all health care providers have been 
required to report hospitalizations since 1987 and physician 
visits in secondary care (i.e., non-primary care) since 2001 
[14]. Each hospitalization or visit is assigned a main diagno-
sis and one or more secondary diagnoses, which indicate the 
purpose(s) of the hospitalization or visit. Medical and surgi-
cal procedures are also recorded. The National Patient Reg-
ister has been validated, showing positive predictive values 
of more than 90% for most diagnoses, although sensitivity 
is often lower [14]. For cancer, we also selected diagnoses 
recorded in the Swedish Cancer Register from 1964 through 
2018, so as to obtain a longer lookback period than is possi-
ble with the National Patient Register. Health-care providers 
have been required to report new cancer diagnoses to the 
Swedish Cancer Register since 1958 [15]. Data on prescrip-
tion medication use were obtained from the Prescribed Drug 
Registry, which records all prescription medications col-
lected at pharmacies in Sweden since July 2005 [16]. Data 
on residence in a long-term care facility and use of home-
maker service were available from the Register for Care and 
Services for the Elderly and for Persons with Impairments 
According to the Social Services Act. Local governments 
are required to report to this register, whose quality is con-
sidered adequate for publication by the National Board of 
Health and Welfare [17]. Homemaker services are domes-
tic services provided to persons (primarily older persons) 
who live at home but need help with shopping, cleaning, 
meal preparation, and similar tasks. Local governments are 
responsible for determining eligibility for these services, 
although the services may be provided by private businesses.
Information about ICU care was obtained from the 
Swedish Intensive Care Registry. In 2019, 83 of Sweden’s 
84 ICUs reported to this registry [18]. The data from the 
registries were linked using the Personal Identification Num-
ber that is issued to each resident of Sweden at the time of 
birth or immigration. We obtained data files in which Per-
sonal Identification Numbers had been replaced by pseudo-
anonymized identifiers, generated by Statistics Sweden. The 
study was approved by the Swedish Ethical Review Author-
ity, who waived the requirement of obtaining informed con-
sent (number 2020–02552).
Variables
We investigated three different outcomes related to COVID-
19 infection, each reflecting an increased severity of infec-
tion: COVID-19 diagnosis without hospitalization; non-ICU 
hospitalization with confirmed COVID-19 as the main diag-
nosis (International Classification of Diseases,  10th Revision, 
Swedish Version, [ICD-10-SE] Code: U071); and ICU hos-
pitalization for confirmed COVID-19 (ICD-10-SE: U071). 
ICU hospitalizations were traced in SmiNet and non-ICU 
hospitalizations were traced in the National Patient Register 
until October 1, 2020. These groups, along with the control 
group, were followed-up for all-cause mortality until Octo-
ber 1, 2020.
Table 1 shows the demographic variables, comorbidi-
ties, and prescription medications that were included in the 
analysis as potential risk factors for COVID-19. Although 
pneumonia is sometimes a complication of COVID-19, we 
included history of pneumonia as a potential risk factor 
because it may be a marker of frailty or impaired immune 
system. Variable definitions are available in Supplemental 
Tables 1 and 2. A composite variable was also constructed, 
which indicated the presence of at least one of the comor-
bidities or medications.
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Table 1  Characteristics COVID-19 cases and controls
Variable Controls (n = 434,081) Diagnosis (n = 68,575) Non-ICU hosp. 
(n = 13,589)
ICU hosp. (n = 2494)
Demographics
 Male sex, n (%) 218,736 (50.4) 26,808 (39.1) 7619 (56.1) 1814 (72.7)
 Age, y
 Mean (SD) 41 (24) 46 (21) 65 (19) 59 (14)
 0–19, n (%) 100,221 (23.1) 4,556 (6.6) 161 (1.2) 25 (1.0)
 20–29, n (%) 54,657 (12.6) 13,128 (19.1) 381 (2.8) 91 (3.6)
 30–39, n (%) 57,490 (13.2) 11,976 (17.5) 821 (6.0) 106 (4.3)
 40–49, n (%) 54,872 (12.6) 12,002 (17.5) 1458 (10.7) 273 (10.9)
 50–59, n (%) 54,808 (12.6) 11,896 (17.3) 2313 (17.0) 640 (25.7)
 60–69, n (%) 47,074 (10.8) 5623 (8.2) 2137 (15.7) 753 (30.2)
 70–79, n (%) 42,182 (9.7) 2946 (4.3) 2550 (18.8) 495 (19.8)
 80–89, n (%) 18,653 (4.3) 3861 (5.6) 2743 (20.2) 107 (4.3)
 ≥ 90, n (%) 4,124 (1.0) 2587 (3.8) 1025 (7.5) 4 (0.2)
 Born in Sweden, n (%) 349,128 (80.4) 51,281 (74.8) 8307 (61.1) 1376 (55.2)
Education in 2018, n (%)
  Missinga 100,490 3,709 767 125
 Primary 66,656 (20.0) 11,837 (18.2) 4088 (31.9) 625 (26.4)
 Secondary 144,543 (43.3) 27,705 (42.7) 5306 (41.4) 1075 (45.4)
 Post-secondary, < 3 y 47,858 (14.3) 9011 (13.9) 1440 (11.2) 292 (12.3)
 Post-secondary, ≥ 3 y 74,534 (22.3) 16,313 (25.1) 1988 (15.5) 377 (15.9)
Family disposable income in 2018, n (%)
  Missinga 88,321 2229 237 43
 Quintile 1 68,766 (19.9) 12,120 (18.3) 4409 (33.0) 575 (23.5)
 Quintile 2 69,086 (20.0) 12,407 (18.7) 2916 (21.8) 522 (21.3)
 Quintile 3 69,225 (20.0) 11,500 (17.3) 2429 (18.2) 487 (19.9)
 Quintile 4 69,343 (20.1) 14,386 (21.7) 1883 (14.1) 432 (17.6)
 Quintile 5 69,340 (20.1) 15,933 (24.0) 1715 (12.8) 435 (17.7)
 Long-term care facility, n (%) 3928 (0.9) 6121 (8.9) 1183 (8.7) 18 (0.7)
 Homemaker service, n (%) 13,144 (3.0) 6825 (10.0) 4507 (33.2) 323 (13.0)
Stockholm  residenceb
 Missing 790 236 69 11
 N (%) 100,008 (23.1) 16,400 (24.0) 5636 (41.7) 895 (36.0)
Comorbitities, n (%)
 Any comorbidity/medication 267,702 (61.7) 50,441 (73.6) 12,464 (91.7) 2218 (88.9)
 Cardiovascular disease 31,922 (7.4) 6438 (9.4) 4433 (32.6) 445 (17.8)
 Hypertension 94,582 (21.8) 16,416 (23.9) 8280 (60.9) 1340 (53.7)
 Cancer 33,251 (7.7) 5515 (8.0) 2861 (21.1) 304 (12.2)
 Immune disorder 1125 (0.3) 207 (0.3) 72 (0.5) 16 (0.6)
 Autoimmune disease 19,372 (4.5) 3655 (5.3) 1551 (11.4) 189 (7.6)
 Diabetes 26,026 (6.0) 4897 (7.1) 3,394 (25.0) 651 (26.1)
 COPD 13,133 (3.0) 2168 (3.2) 1,578 (11.6) 169 (6.8)
 Asthma 27,746 (6.4) 4493 (6.6) 1,208 (8.9) 211 (8.5)
 Renal failure/chronic kidney disease 4720 (1.1) 1353 (2.0) 1,351 (9.9) 130 (5.2)
 Glomerular disease 1569 (0.4) 337 (0.5) 213 (1.6) 42 (1.7)
 Liver disease 2628 (0.6) 511 (0.7) 285 (2.1) 66 (2.6)
 Dementia/Alzheimer’s disease 3665 (0.8) 3618 (5.3) 870 (6.4) 8 (0.3)
 Down syndrome 297 (0.1) 57 (0.1) 20 (0.1) 8 (0.3)
 HIV/AIDS 357 (0.1) 84 (0.1) 32 (0.2) 9 (0.4)
 Sepsis 3448 (0.8) 1018 (1.5) 683 (5.0) 78 (3.1)
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Statistical analysis
Multinomial logistic regression was used to estimate odds 
ratios for COVID-19 diagnosis or ICU or non-ICU hos-
pitalization. Cox regression was used to estimate hazard 
ratios for mortality. In each model, persons were excluded 
if they had missing data on at least one of the included 
variables.
For non-hospitalized COVID-19 cases, baseline date 
was defined as the date of testing or diagnosis, whichever 
came first or was available. If both dates were unavailable, 
the case was excluded from the analysis. Baseline date for 
hospitalized cases was the date of ICU or non-ICU admis-
sion. For controls, we randomly sampled a date from the 
baseline dates among cases. Controls who had died by 
their sampled date were excluded from the analysis.
A subgroup analysis was conducted to examine the 
prevalence of risk factors for COVID-19 and subsequent 
mortality in the age group 0–19 years. We did not estimate 
odds ratios and hazard ratios in this age group because of 
the small number of deaths and hospitalized COVID-19 
cases.
The incidence of COVID-19 was estimated by dividing 
the number of cases by the size of the Swedish population (in 
total and by age group and sex) on December 31, 2019 [19]. 
The Kaplan–Meier method was used to estimate mortality 
rates, with confidence intervals based on the log(survival) 
transformation. All statistical analyses were performed in 
RStudio (R version 3.6.2). Statistical significance was deter-
mined by 95% confidence intervals not overlapping 1.
Results
There were 87,069 confirmed cases of COVID-19 (inci-
dence rate in Swedish population: 843 cases/100,000 
population) and 435,345 general-population controls. Of 
the cases, 84,633 (97.2%) had an available date of testing 
and/or diagnosis, which ranged from January 30, 2020, to 
September 27, 2020. Most cases were diagnosed between 
April and June (Supplemental Fig. 1). The incidence was 
higher in women than in men in most age groups (Supple-
mental Fig. 2). The incidence was lowest in the age group 
0–19 years and highest in the age group ≥ 90 years.
By October 1, 2020, 13,589 (15.6%) of the COVID-19 
cases had been non-ICU hospitalized for confirmed COVID-
19 and 2,494 (2.9%) had been ICU hospitalized. The 16,083 
hospitalized patients lived in 14,936 different households 
(479 [3.0%] patients had missing data on household). Of 
these households, 95.7% (n = 14,287) had only one hospi-
talized household member (mean 1.04 hospitalized persons 
per household).
Risk factors for COVID‑19 diagnosis 
and hospitalization
In the analysis of risk factors for COVID-19 diagnosis and 
hospitalization, 1264 controls were excluded because they 
died prior to their assigned baseline date. Furthermore, 2411 
non-hospitalized COVID-19 cases were excluded because no 
date of testing or diagnosis was available.
COPD chronic obstructive pulmonary disease, HIV/AIDS human immunodeficiency virus/acquired immunodeficiency syndrome, hosp. hospi-
talization, ICU intensive care unit, SD standard deviation
a Part of the missing data on education and family income was due to a lack of data on persons aged < 15 years on Dec 31, 2018: 83,198 persons 
in the control group; 1,616 persons in the diagnosis-only group; 108 persons in the non-ICU hospitalized group; and 15 persons in the ICU hos-
pitalized group
b Residence in Stockholm County (the capital of Sweden) refers to December 31, 2019
Table 1  (continued)
Variable Controls (n = 434,081) Diagnosis (n = 68,575) Non-ICU hosp. 
(n = 13,589)
ICU hosp. (n = 2494)
 Influenza 3074 (0.7) 922 (1.3) 538 (4.0) 58 (2.3)
 Pneumonia 17,422 (4.0) 3861 (5.6) 2193 (16.1) 234 (9.4)
 Solid organ transplantation 408 (0.1) 85 (0.1) 110 (0.8) 25 (1.0)
 Alcohol intoxication 11,754 (2.7) 2092 (3.1) 605 (4.5) 119 (4.8)
Prescription medications, n (%)
 Antithrombotics 71,744 (16.5) 13,797 (20.1) 6945 (51.1) 941 (37.7)
 Lipid-modifying agents 58,383 (13.4) 9,168 (13.4) 5652 (41.6) 914 (36.6)
 Proton-pump inhibitors 111,107 (25.6) 24,016 (35.0) 7726 (56.9) 1226 (49.2)
 Corticosteroids, systemic 87,788 (20.2) 17,651 (25.7) 5543 (40.8) 879 (35.2)
 Immunosuppressants 8724 (2.0) 1,614 (2.4) 782 (5.8) 137 (5.5)
 Antivirals 32,695 (7.5) 7,624 (11.1) 1851 (13.6) 286 (11.5)
 Opioids 137,169 (31.6) 29,214 (42.6) 8852 (65.1) 1410 (56.5)
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Risk factors for COVID-19 diagnosis and hospitaliza-
tion are presented in Tables 1 and 2. The majority of non-
hospitalized COVID-19 cases were women, but the majority 
of hospitalized cases were men. After adjustment for other 
risk factors, the odds of non-ICU hospitalization increased 
until the age group 40–49 years, after which there was no 
observable trend. Both the adjusted and unadjusted odds of 
ICU admission increased until the age group 60–69 years 
and decreased thereafter.
Being born in Sweden was associated with lower odds of 
COVID-19 diagnosis and hospitalization (Table 2). Higher 
levels of education were associated with higher odds of 
COVID-19 diagnosis but with lower odds of hospitalization. 
After adjustment for other risk factors, family disposable 
income was positively associated with COVID-19 diagnosis, 
but there was no clear association with hospitalization.
After adjustment for other risk factors, residence in a 
long-term care facility was associated with increased odds 
of diagnosis and, albeit to a lesser degree, non-ICU hospi-
talization (Table 2). Residence in a long-term care facility 
was associated with lower odds of ICU admission. Use of 
homemaker service was associated with both COVID-19 
diagnosis and hospitalization (ICU and non-ICU).
Approximately 90% of ICU and non-ICU hospitalized 
patients had at least one of the investigated comorbidities 
or medications, and this was associated with more than 
twice the odds of ICU and non-ICU hospitalization after 
adjustment for demographic factors (Tables 1 and 2). The 
two comorbidities most strongly associated with ICU and 
non-ICU hospitalization after adjustment for other risk fac-
tors were diabetes and Down syndrome. Other comorbidi-
ties associated with both ICU and non-ICU hospitalization 
were hypertension, immune disorder, asthma, influenza, 
and pneumonia. Comorbidities significantly associated with 
increased odds of either ICU or non-ICU admission, but not 
with both, were autoimmune disease, chronic obstructive 
pulmonary disease (COPD), renal failure/chronic kidney 
disease, sepsis, solid organ transplantation, and liver dis-
ease. Human immunodeficiency virus/acquired immunode-
ficiency syndrome (HIV/AIDS) and glomerular disease were 
non-significantly associated with both ICU and non-ICU 
hospitalization. Alcohol intoxication was associated with 
lower odds of COVID-19 diagnosis and hospitalization after 
adjustment for other risk factors.
Cancer was not associated with increased odds of hospi-
talization after adjustment for other risk factors (Table 2). 
The unadjusted association was explained by sex, age group, 
hypertension, cardiovascular disease, corticosteroid use, and 
opioid use (Supplemental Table 3). Cancer in the past year, 
however, was associated with COVID-19 diagnosis and 
non-ICU hospitalization, but not with ICU hospitalization, 
after adjustment for all variables in Table 2 other than Any 
Comorbidity/Medication (adjusted odds ratio for diagnosis 
1.17, 1.09–1.26; adjusted odds ratio for non-ICU hospitali-
zation 1.30, 95% CI 1.20–1.42; adjusted odds ratio for ICU 
admission 0.90, 95% CI 0.72–1.12).
Cardiovascular disease was associated with slightly 
increased odds of non-ICU hospitalization, but with lower 
odds of ICU admission, after adjustment for other risk fac-
tors (Table 2). The unadjusted association of cardiovascular 
disease with ICU admission was explained by age group, 
sex, hypertension, and diabetes (Supplemental Table 4).
Antithrombotics, proton-pump inhibitors, corticosteroids, 
and opioids were associated with both ICU and non-ICU 
hospitalization for COVID-19 after adjustment other risk 
factors (Table 2). Antivirals and lipid-modifying agents were 
not associated with either ICU or non-ICU hospitalization 
after controlling for other risk factors. The unadjusted asso-
ciation for lipid-modifying agents was explained by age, sex, 
hypertension, diabetes, and cardiovascular disease (Supple-
mental Table 5). Immunosuppressants were associated with 
increased odds of ICU hospitalization and slightly increased 
odds of non-ICU hospitalization, although the associations 
were not significant.
All‑cause mortality in COVID‑19
In the analysis of all-cause mortality, an additional 45 non-
hospitalized COVID-19 cases were excluded because they 
died prior to the date of testing or diagnosis. The median 
number of days from baseline until the end date of the anal-
ysis (October 1, 2020) was 119 days (interquartile range, 
98–155 days).
Excess mortality was observed in hospitalized and non-
hospitalized COVID-19 cases after adjustment for other risk 
factors (Fig. 1, Table 3, Table 4). The only demographic 
factor not associated with all-cause mortality was birth 
in Sweden (Table 4). Most comorbidities were associated 
with mortality in excess of any risk conferred by COVID-
19 (Table 4).
COVID‑19 and subsequent mortality in persons 
aged 0–19 years
Male sex was not associated with COVID-19 diagnosis or 
ICU or non-ICU hospitalization in persons aged 0–19 years 
(Supplemental Table 6). Hospitalized COVID-19 cases 
were less often born in Sweden, and they more often had 
hypertension, cancer, diabetes, COPD, sepsis, pneumonia, 
and corticosteroid use than did general-population controls 
and non-hospitalized COVID-19 cases. Asthma and proton-
pump inhibitors were more common in non-ICU hospital-
ized and diagnosis-only COVID-19 cases than in general-
population controls. There were too few deaths to evaluate 
excess mortality among COVID-19 cases aged 0–19 years 
(Supplemental Table 7).
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Table 2  Association between potential risk factors and COVID-19 (reference group: general population controls)
Variable Unadjusted Odds Ratio (95% CI) Adjusteda Odds Ratio (95% CI)
Diagnosis Non-ICU hosp. ICU hosp. Diagnosis Non-ICU hosp. ICU hosp.
Demographics
 Male sex 0.63 (0.62–0.64) 1.26 (1.21–1.30) 2.63 (2.41–2.87) 0.64 (0.63–0.65) 1.59 (1.53–1.65) 3.04 (2.76–3.35)
 Age group, y
   0–19 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
  20–29 5.28 (5.10–5.47) 4.34 (3.61–5.22) 6.67 (4.29–10.39) 0.69 (0.66–0.73) 2.45 (1.69–3.55) 3.62 (1.45–9.02)
  30–39 4.58 (4.42–4.75) 8.89 (7.51–10.53) 7.39 (4.78–11.43) 0.47 (0.44–0.50) 4.12 (2.86–5.93) 3.70 (1.49–9.21)




0.46 (0.43–0.49) 7.25 (5.05–10.41) 9.68 (3.94–23.77)




0.45 (0.42–0.48) 10.17 (7.09–14.60) 20.30 (8.30–49.64)




0.24 (0.22–0.25) 8.46 (5.89–12.14) 23.97 (9.80–58.62)




0.10 (0.09–0.11) 7.31 (5.08–10.50) 14.59 (5.94–35.81)









3.88 (1.35–11.17) 0.18 (0.16–0.19) 10.17 (7.02–14.75) 0.84 (0.22–3.19)
 Born in Sweden 0.72 (0.71–0.74) 0.38 (0.37–0.40) 0.30 (0.28–0.32) 0.71 (0.69–0.72) 0.38 (0.37–0.40) 0.33 (0.30–0.37)
 Education in 
2018
 Primary 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
 Secondary 1.08 (1.05–1.10) 0.60 (0.57–0.62) 0.79 (0.72–0.88) 1.11 (1.08–1.15) 0.87 (0.83–0.91) 0.91 (0.82–1.01)
 Post-second-
ary, < 3 y
1.06 (1.03–1.09) 0.49 (0.46–0.52) 0.65 (0.57–0.75) 1.09 (1.05–1.13) 0.79 (0.74–0.85) 0.80 (0.69–0.92)
 Post-second-
ary, ≥ 3 y
1.23 (1.20–1.26) 0.43 (0.41–0.46) 0.54 (0.47–0.61) 1.19 (1.15–1.23) 0.73 (0.69–0.78) 0.73 (0.63- 0.83)
 Disposable fam-
ily income in 
2018
   Quintile 1 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
   Quintile 2 1.02 (0.99–1.05) 0.66 (0.63–0.69) 0.90 (0.80–1.02) 1.30 (1.26–1.35) 0.98 (0.92–1.04) 0.93 (0.81–1.07)
   Quintile 3 0.94 (0.92–0.97) 0.55 (0.52–0.58) 0.84 (0.75–0.95) 1.74 (1.69–1.80) 1.07 (1.00–1.14) 0.96 (0.83–1.10)
   Quintile 4 1.18 (1.15–1.21) 0.42 (0.40–0.45) 0.75 (0.66–0.84) 1.88 (1.82–1.95) 0.99 (0.92–1.07) 0.94 (0.81–1.08)





10.44 (9.76–11.17) 0.80 (0.50–1.27) 9.96 (9.33–10.63) 1.17 (1.07–1.27) 0.39 (0.24- 0.63)
 Homemaker 
service
3.54 (3.43–3.65) 15.89 (15.27–
16.54)
4.76 (4.23–5.36) 2.24 (2.12–2.37) 5.30 (4.99–5.63) 4.53 (3.90–5.25)
 Stockholm 
 residenceb




1.73 (1.70–1.76) 6.89 (6.48–7.32) 4.99 (4.41–5.66) 1.31 (1.29–1.34)c 2.39 (2.23–2.57)c 2.17 (1.88–2.50)c
 Cardiovascular 
disease
1.31 (1.27–1.34) 6.10 (5.88–6.34) 2.74 (2.47–3.03) 1.10 (1.05–1.15) 1.08 (1.02–1.14) 0.74 (0.65–0.85)
 Hypertension 1.13 (1.11–1.15) 5.60 (5.40–5.80) 4.17 (3.85–4.51) 1.00 (0.97–1.03) 1.24 (1.18–1.31) 1.42 (1.27–1.58)
 Cancer 1.05 (1.02–1.09) 3.21 (3.08–3.36) 1.67 (1.48–1.89) 0.97 (0.93–1.00) 1.01 (0.96–1.07) 0.81 (0.71–0.93)
 Immune disorder 1.17 (1.00–1.35) 2.05 (1.61–2.60) 2.48 (1.51–4.08) 1.01 (0.86–1.19) 1.33 (1.01–1.73) 1.79 (1.04–3.09)
 Autoimmune 
disease
1.21 (1.16–1.25) 2.76 (2.61–2.91) 1.76 (1.51–2.04) 0.97 (0.93–1.02) 1.13 (1.05–1.21) 0.95 (0.80–1.14)
 Diabetes 1.21 (1.17–1.24) 5.22 (5.01–5.44) 5.54 (5.07–6.07) 1.13 (1.09–1.18) 1.54 (1.46–1.62) 1.82 (1.62–2.03)
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Discussion
This nationwide study confirmed that older age, male sex, 
and comorbidity in general are risk factors for COVID-19 
hospitalization and, with the exception of male sex, risk 
factors for COVID-19 diagnosis without hospitalization. 
Older age was the strongest risk factor for COVID-19 hos-
pitalization, but the odds of non-ICU hospitalization showed 
no trend after 40–49 years after adjustment for other risk 
factors, and the odds of ICU admission decreased after 
60–69 years (with or without adjustment). Furthermore, 
persons living in long-term care facilities were rarely ICU 
admitted. Excess all-cause mortality was observed in both 
hospitalized and non-hospitalized cases, even after control-
ling for a large number of comorbidities and demographic 
factors. Children and young people aged 0–19 years were 
rarely diagnosed with or hospitalized for COVID-19, and 
there were too few deaths in this age group to evaluate 
excess mortality.
Almost all (90%) hospitalized patients had one of the 
investigated comorbidities or medications, and this was asso-
ciated with more than twice the odds of ICU and non-ICU 
hospitalization for COVID-19. As in previous studies [5–7], 
age was the strongest risk factor for severe COVID-19, and 
COPD chronic obstructive pulmonary disease, HIV/AIDS human immunodeficiency virus/acquired immunodeficiency syndrome, hosp. hospi-
talization, ICU intensive care unit
a Adjusted for all variables in column 1 except for Any Comorbidity/Medication
b Residence in Stockholm County (the capital of Sweden) refers to December 31, 2019
c Adjusted for all demographic variables
Table 2  (continued)
Variable Unadjusted Odds Ratio (95% CI) Adjusteda Odds Ratio (95% CI)
Diagnosis Non-ICU hosp. ICU hosp. Diagnosis Non-ICU hosp. ICU hosp.
 COPD 1.05 (1.00–1.10) 4.21 (3.98–4.45) 2.33 (1.99–2.73) 1.07 (1.01–1.13) 1.37 (1.28–1.47) 1.12 (0.94–1.34)




1.83 (1.72–1.95) 10.04 (9.43–10.70) 5.00 (4.18–5.98) 1.29 (1.19–1.39) 1.47 (1.36–1.60) 1.18 (0.95–1.46)
 Glomerular 
disease
1.35 (1.20–1.52) 4.17 (3.60–4.83) 4.33 (3.14–5.97) 1.03 (0.90–1.17) 1.20 (1.00–1.43) 1.40 (0.97–2.02)
 Liver disease 1.23 (1.12–1.36) 3.52 (3.11–3.98) 4.46 (3.48–5.72) 0.99 (0.90–1.10) 1.07 (0.93–1.23) 1.37 (1.05–1.79)
 Dementia/Alzhei-
mer’s disease
6.54 (6.24–6.85) 8.03 (7.45–8.67) 0.38 (0.19–0.76) 1.92 (1.79–2.05) 1.09 (0.99–1.20) 0.15 (0.07–0.31)
 Down syndrome 1.21 (0.91–1.61) 2.16 (1.37–3.40) 4.52 (2.21–9.25) 1.77 (1.04–2.99) 3.24 (1.55–6.78) 4.26 (1.01–17.90)
 HIV/AIDS 1.50 (1.18–1.90) 3.17 (2.24–4.49) 4.87 (2.58–9.18) 0.99 (0.77–1.28) 1.13 (0.76–1.68) 1.45 (0.73–2.89)
 Sepsis 1.88 (1.75–2.02) 6.61 (6.08–7.19) 4.23 (3.38–5.28) 1.25 (1.15–1.36) 1.20 (1.08–1.33) 1.23 (0.96–1.59)
 Influenza 1.92 (1.78–2.06) 5.76 (5.24–6.32) 3.47 (2.68–4.49) 1.23 (1.13–1.34) 1.47 (1.31–1.64) 1.36 (1.02–1.80)
 Pneumonia 1.43 (1.38–1.48) 4.60 (4.39–4.83) 2.47 (2.16–2.83) 1.12 (1.07–1.17) 1.44 (1.35–1.53) 1.22 (1.05–1.43)
 Solid organ trans-
plantation
1.32 (1.04–1.67) 8.68 (7.02–10.72) 10.76 (7.17–16.15) 0.92 (0.71–1.19) 1.41 (1.07–1.84) 1.36 (0.82–2.26)
 Alcohol intoxica-
tion
1.13 (1.08–1.19) 1.68 (1.54–1.82) 1.80 (1.50–2.17) 0.86 (0.82–0.90) 0.76 (0.69–0.84) 0.80 (0.66- 0.97)
Prescription medi-
cations
 Antithrombotics 1.27 (1.25–1.30) 5.28 (5.10–5.47) 3.06 (2.82–3.32) 1.01 (0.98–1.04) 1.19 (1.13–1.25) 1.18 (1.06–1.32)
 Lipid-modifying 
agents
0.99 (0.97–1.02) 4.59 (4.43–4.75) 3.72 (3.43–4.04) 0.95 (0.91–0.98) 0.98 (0.93–1.03) 0.98 (0.87–1.09)
 Proton-pump 
inhibitors
1.57 (1.54–1.59) 3.83 (3.70–3.97) 2.81 (2.60–3.04) 1.16 (1.14–1.19) 1.32 (1.27–1.38) 1.22 (1.11–1.33)
 Corticosteroids, 
systemic
1.37 (1.34–1.39) 2.72 (2.62–2.81) 2.14 (1.97–2.33) 1.11 (1.09–1.14) 1.26 (1.21–1.32) 1.27 (1.16–1.40)
 Immunosuppres-
sants
1.18 (1.11–1.24) 2.98 (2.76–3.21) 2.83 (2.38–3.37) 0.90 (0.85–0.97) 1.08 (0.98–1.20) 1.22 (0.97–1.54)
 Antivirals 1.54 (1.50–1.58) 1.94 (1.84–2.04) 1.59 (1.40–1.80) 1.17 (1.14–1.20) 1.04 (0.99–1.11) 1.04 (0.91–1.19)
Opioids 1.61 (1.58–1.63) 4.05 (3.90–4.19) 2.82 (2.60–3.05) 1.16 (1.14–1.18) 1.34 (1.28–1.40) 1.16 (1.05–1.27)
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none of the comorbidities or medications stood out as a 
particularly important risk factor for COVID-19 diagnosis 
or hospitalization. However, Down syndrome, although 
uncommon, was the condition most strongly associated with 
COVID-19 hospitalization after adjustment for other risk 
factors. Down syndrome was also associated with increased 
all-cause mortality. Previous data on Down syndrome as a 
risk factor for COVID-19 are limited but consistent with 
this result [20].
Our study also showed that both diabetes and hyperten-
sion were highly prevalent and positively associated with 
both ICU and non-ICU hospitalization for COVID-19. In 
previous studies, diabetes has often [5–7, 12], but not always 
[8, 9], been significantly associated with severe COVID-
19 or COVID-19 mortality after controlling for other risk 
factors. Previous results for hypertension have been more 
contradictory [5–9]. We have no explanation for this. We 
defined hypertension as either a diagnosis of hypertension 
or a history antihypertensive treatment, so as to increase the 
sensitivity of detecting hypertension in the study population. 
Some antihypertensive treatments, namely angiotensin-con-
verting enzyme inhibitors and angiotensin II receptor block-
ers, have been suspected to increase the risk of contracting 
COVID-19 and of developing severe COVID-19. However, 
three previous observational studies found no association 
with COVID-19 diagnosis [11, 21, 22], and only one of these 
found an association with severe COVID-19 [22]. Two clini-
cal trials also showed that continuation of antihypertensive 
treatment did not lead to worse outcomes in hospitalized 
COVID-19 cases [23, 24]. Therefore, it is unlikely that the 
association with COVID-19 hospitalization in our study is 
due to an effect of the antihypertensive medications.
After adjustment for other risk factors, we found only a 
weak association between cardiovascular disease and non-
ICU hospitalization for COVID-19, and we found no asso-
ciation with ICU hospitalization. This result contradicts the 
findings of systematic reviews and meta-analyses [25–27]. 
Previous observational studies have shown conflicting 
results, perhaps in part due to differences in definition [5, 7, 
8]. Our results suggest that the association between cardio-
vascular disease and COVID-19 hospitalization is primarily 
driven by age, sex, hypertension, and diabetes.
We found that cancer in the past year, but not ever his-
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Fig. 1  Risk of all-cause mortality in Swedish COVID-19 cases 
(intensive care unit [ICU] hospitalized, non-ICU hospitalized, and 
diagnosed only) confirmed by mid-September 2020 and in general-
population controls
Table 3  All-cause mortality in COVID-19 cases and general population controls
hosp. hospitalization, ICU intensive care unit
Variable Control (n = 434,081) Diagnosis (n = 68,530) Non-ICU hosp. (n = 13,589) ICU hosp. (n = 2,494)
Number of deaths
 30 days 248 2792 2279 565
 60 days 483 2999 2436 643
 90 days 706 3098 2501 657
Total 1059 3286 2612 668
Person-months at risk 1,737,135 245,211 54,671 9516
Mortality rate/1,000 
person-months
0.6 13.4 47.8 70.2
Mortality, % (95% CI)
 30 days 0.1 (0.1–0.1) 4.1 (3.9–4.2) 16.8 (16.2–17.4) 22.7 (21.0–24.3)
 60 days 0.1 (0.1–0.1) 4.4 (4.3–4.6) 18.0 (17.3–18.6) 25.8 (24.1–27.6)
 90 days 0.2 (0.2–0.2) 4.6 (4.4–4.7) 18.5 (17.8–19.1) 26.4 (24.7–28.1)
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Table 4  Potential risk factors for all-cause mortality
Variable Hazard Ratio (95% CI)




 Control 1 (ref) 1 (ref) 1 (ref)
 Diagnosis only 20.54 (19.17–22.02) 18.98 (17.67–20.37) 10.03 (9.27–10.86)
 Non-ICU hospitalization 84.36 (78.54–90.61) 26.38 (24.54–28.36) 17.34 (16.04–18.75)
 ICU hospitalization 120.26 (109.15–132.49) 92.92 (84.17–102.58) 77.41 (69.83–85.80)
Demographics
 Male sex 1.14 (1.09–1.19) 1.56 (1.49–1.64) 1.67 (1.59–1.76)
Age group, y
 0–19 1 (ref) 1 (ref) 1 (ref)
 20–29 3.09 (1.32–7.23) 1.23 (0.53–2.88) 0.52 (0.17–1.62)
 30–39 3.92 (1.74–8.84) 1.62 (0.72–3.66) 0.62 (0.21–1.88)
 40–49 12.98 (6.24–27.01) 4.74 (2.28–9.86) 2.18 (0.79–6.00)
 50–59 42.29 (20.89–85.59) 13.27 (6.55–26.88) 5.33 (1.98–14.37)
 60–69 133.04 (66.21–267.34) 47.23 (23.49–94.96) 13.70 (5.10–36.76)
 70–79 456.41 (227.87–914.17) 201.51 (100.55–403.84) 36.27 (13.53–97.23)
 80–89 1683.57 (841.20–3369.51) 541.32 (270.30–1084.07) 67.65 (25.23–181.44)
 ≥ 90 3819.71 (1907.57–7648.56) 846.33 (422.31–1696.08) 93.13 (34.69–249.97)
 Born in Sweden 1.02 (0.97–1.08) 0.96 (0.90–1.01) 1.00 (0.94–1.07)
Education in 2018
 Primary 1 (ref) 1 (ref) 1 (ref)
 Secondary 0.42 (0.40–0.44) 0.93 (0.89–0.98) 0.96 (0.92–1.02)
 Post-secondary, < 3 y 0.27 (0.25–0.29) 0.83 (0.76–0.90) 0.89 (0.81–0.97)
 Post-secondary, ≥ 3 y 0.21 (0.20–0.23) 0.72 (0.67–0.78) 0.83 (0.77–0.91)
Disposable family income in 2018
 Quintile 1 1 (ref) 1 (ref) 1 (ref)
 Quintile 2 0.43 (0.41–0.46) 0.78 (0.74–0.83) 0.88 (0.83–0.93)
 Quintile 3 0.24 (0.22–0.26) 0.67 (0.62–0.72) 0.79 (0.73–0.85)
 Quintile 4 0.11 (0.10–0.12) 0.57 (0.52–0.64) 0.71 (0.64–0.79)
 Quintile 5 0.09 (0.08–0.10) 0.54 (0.49–0.61) 0.67 (0.59–0.74)
 Long-term care facility 42.64 (40.76–44.61) 2.30 (2.17–2.44) 1.74 (1.63–1.85)
 Homemaker service 42.55 (40.58–44.62) 1.91 (1.80–2.03) 1.41 (1.32–1.49)
 Stockholm  residenceb 1.91 (1.82–2.00) 1.18 (1.12–1.23) 1.09 (1.04–1.15)
Comorbitities
 Any comorbidity/medication 43.72 (35.79–53.42) 2.57 (2.09–3.16) 2.34 (1.88–2.91)c
 Cardiovascular disease 14.85 (14.19–15.54) 1.44 (1.37–1.51) 1.13 (1.07–1.20)
 Hypertension 19.07 (17.91–20.31) 1.58 (1.47–1.69) 1.22 (1.14–1.32)
 Cancer 6.47 (6.17–6.78) 1.16 (1.11–1.22) 1.14 (1.08–1.19)
 Immune disorder 1.78 (1.29–2.46) 1.32 (0.96–1.82) 1.07 (0.77–1.48)
 Autoimmune disease 3.37 (3.16–3.59) 1.24 (1.16–1.32) 1.08 (1.00–1.16)
 Diabetes 5.86 (5.58–6.16) 1.39 (1.32–1.46) 1.23 (1.16–1.30)
 COPD 5.53 (5.20–5.89) 1.35 (1.27–1.44) 1.08 (1.01–1.16)
 Asthma 1.22 (1.12–1.33) 1.04 (0.95–1.13) 0.85 (0.78–0.93)
 Renal failure/chronic kidney disease 14.83 (13.96–15.74) 1.69 (1.59–1.79) 1.30 (1.22–1.39)
 Glomerular disease 3.28 (2.70–3.99) 1.48 (1.22–1.81) 0.87 (0.70–1.07)
 Liver disease 4.10 (3.57–4.72) 1.74 (1.51–2.00) 1.27 (1.09–1.46)
 Dementia/Alzheimer’s disease 28.29 (26.92–29.73) 1.90 (1.80–2.01) 1.60 (1.50–1.70)
 Down syndrome 2.70 (1.62–4.47) 15.15 (9.09–25.24) 10.91 (5.41–22.02)
296 J. Bergman et al.
1 3
hospitalization. This finding corroborates the results of three 
previous observational studies and a meta-analysis [6–8, 27]. 
Altogether, only recent cancer appears to be associated with 
an increased risk of developing severe COVID-19, which 
could be due to the underlying treatment (e.g., chemotherapy 
and other medications that affect the immune system).
Our study showed that both COPD and asthma were 
associated with COVID-19 hospitalization, but only COPD 
was associated with all-cause mortality after adjustment for 
COVID-19, age group, and sex. Previous studies have shown 
conflicting results concerning the association between 
asthma and COPD and severe COVID-19 or mortality [4, 
6, 7]. It is possible that the positive association in our study 
applies only to severe asthma, as we only had data on diag-
noses made in secondary care and hospitalized care.
Concerning demographic factors, the burden of COVID-
19 was greater in foreign-born persons, as they were more 
often diagnosed and hospitalized, although all-cause mortal-
ity was not higher in foreign-born persons. There was not a 
clear association between income and COVID-19 hospitali-
zation, although having a disposable family income in the  3rd 
to  5th quintiles was associated with higher odds of COVID-
19 diagnosis without hospitalization. Persons with higher 
levels of education were more often diagnosed and less often 
hospitalized with COVID-19. This association with COVID-
19 diagnosis may at least in part be caused by more frequent 
testing of health care professionals than of the general popu-
lation. Residence in a long-term care facility was a strong 
risk factor for COVID-19 diagnosis and subsequent all-cause 
mortality, although the association with non-ICU hospitali-
zation was weaker and residents of long-term care facilities 
were rarely ICU admitted. It is well-known that long-term 
care facilities for older people have been severely affected 
by COVID-19 [28], but data on such residence has not been 
available in several large epidemiologic studies [4, 6–8]. Our 
results confirm that it is important to keep COVID-19 out of 
long-term care facilities.
A number limitations of this study need to be mentioned. 
First, the associations presented in this study are not neces-
sarily causal, as there may be residual or unmeasured con-
founding. Second, the presence of some medical conditions, 
especially mild conditions, may be underestimated because 
primary-care diagnoses and complete histories of medical 
conditions were not available. Third, the likelihood that a 
person tests positive for COVID-19 is related not only to 
his or her risk of being infected, but also to his or her access 
to testing, willingness to be tested, and severity of symp-
toms. The Swedish strategy for testing was initially to pri-
oritize hospitalized patients, health care professionals, and 
residents of long-term care facilities [29]. In April 2020, 
the strategy was extended to include personnel in essential 
sectors other than health care [30], and in June 2020, the 
Table 4  (continued)
Variable Hazard Ratio (95% CI)
Unadjusted Adjusted for age group, sex, and 
COVID-19
Fully  adjusteda
 HIV/AIDS 0.85 (0.38–1.89) 1.24 (0.56–2.77) 0.80 (0.33–1.94)
 Sepsis 10.10 (9.33–10.93) 1.51 (1.39–1.63) 1.12 (1.03–1.22)
 Influenza 6.28 (5.67–6.95) 1.26 (1.14–1.39) 0.93 (0.84–1.04)
 Pneumonia 7.57 (7.20–7.97) 1.61 (1.53–1.70) 1.30 (1.23–1.38)
 Solid organ transplantation 5.03 (3.75–6.74) 3.02 (2.25–4.05) 1.66 (1.19–2.32)
 Alcohol intoxication 2.12 (1.93–2.34) 1.55 (1.40–1.71) 1.12 (1.02–1.24)
Prescription medications
 Antithrombotics 15.14 (14.36–15.97) 1.50 (1.41–1.59) 1.16 (1.09–1.25)
 Lipid-modifying agents 7.58 (7.25–7.93) 1.15 (1.10–1.21) 0.93 (0.88–0.98)
 Proton-pump inhibitors 4.36 (4.16–4.57) 1.25 (1.20–1.31) 1.03 (0.98–1.08)
 Corticosteroids, systemic 2.95 (2.82–3.08) 1.20 (1.15–1.26) 1.11 (1.05–1.17)
 Immunosuppressants 2.51 (2.27–2.77) 1.26 (1.14–1.39) 1.00 (0.89–1.13)
 Antivirals 2.00 (1.88–2.13) 1.04 (0.97–1.10) 0.98 (0.92–1.05)
 Opioids 5.80 (5.51–6.10) 1.35 (1.28–1.42) 1.16 (1.09–1.22)
COPD chronic obstructive pulmonary disease, HIV/AIDS human immunodeficiency virus/acquired immunodeficiency syndrome, hosp. hospi-
talization, ICU intensive care unit
a Adjusted for all variables in column 1 except for Any Comorbidity/Medication
b On December 31, 2019
c Adjusted for the demographic variables
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strategy was extended to all persons with symptoms [31]. 
This fact may have biased our results for non-hospitalized 
COVID-19 cases, especially because most cases were diag-
nosed between April and June. However, the testing strategy 
should not have affected our results for hospitalized cases. 
Fourth, data on smoking and body mass index were not 
available. The strengths of the study include its nationwide 
coverage and the availability of many previously suspected 
risk factors for severe COVID-19. These strengths increase 
the internal and external validity of the results.
In summary, this nationwide study confirmed that severe 
COVID-19 is related to age, sex, and general health rather 
than particular medical conditions. As previously shown, 
diabetes was a strong risk factor, and only recent cancer was 
associated with severe COVID-19. Cardiovascular disease 
was weakly associated with COVID-19 hospitalization after 
controlling for other risk factors. This study provides new 
evidence that hypertension, asthma, Down syndrome, and 
residence in a long-term care facility are associated with 
severe COVID-19. Excess all-cause mortality was observed 
in both hospitalized and non-hospitalized COVID-19 cases.
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